

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: John Jairo LOPEZ AREIZA, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/EP03/15033

GAU:

FILED: Herewith

EXAMINER:

FOR: AZA-PEPTIDES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)Surinder Sachar
Registration No. 34,423

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 270932US0PCT		SERIAL NO. 10/537246 New U.S. PCT Application Based on PCT/EP03/15033	
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT John Jairo LOPEZ AREIZA, et al.					
		FILING DATE Herewith		GROUP			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5 948 763	09/07/99	SOTO-JARA et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AB	01/34631	05/17/01	WO	YES	NO	
	AC	96/39834	12/19/96	WO			NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
AD	HAN, Hyunsoo et al. "Azatides: Solution and Liquid Phase Syntheses of a New Peptidomimetic", Journal of the American Chemical Society, vol. 118, no. 11, pages 2539-2544, XP002046408 1996						
AE	HETENYI, C. et al. "Computational studies on the binding of beta-sheet breaker (BSB) peptides on amyloid betaA(1-42)", Journal of Molecular Structure (Theochem), vol. 542, pages 25-31, XP001146365 2001						
AF	GANTE, Joachim. "Azapeptides", Synthesis, no. 6, pages 405-413, XP000035384 1989						
AG	SELKOE, Dennis J. "Alzheimer's Disease: Genotypes, Phenotype, and Treatments", Science, vol. 275, pages 630-631 1997						
AH	MASTERS, Colin L. et al. "Amyloid plaque core protein in Alzheimer disease and Down syndrome", Proc. Natl. Acad. Sci., vol. 82, pages 4245-4249 1985						
AI	DAVIES, L. et al. "A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: Prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques", Neurology, vol. 38, pages 1688-1693 1988						
AJ	KOWALL, Neil W. et al. "An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P", Proc. Natl. Acad. Sci., vol. 88, pages 7247-7251 1991						
AK	LEVY, Efrat et al. "Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type", Science, vol. 248, pages 1124-1126 1990						
AL	MAURY, C.P.J. "Biology of Disease: Molecular Pathogenesis of beta-Amyloidosis in Alzheimer's Disease and Other Cerebral Amyloidoses", Laboratory Investigation, vol. 72, no. 1, pages 4-16 1995						
AM	JORDAN, Barry D. "Chronic Traumatic Brain Injury Associated with Boxing", Seminars in Neurology, vol. 20, no. 2, pages 179-185 2000						
AN	KANG, Jie et al. "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor", Nature, vol. 325, pages 733-736 1987						
AO	MANN, D.M.A. "Alzheimer's disease and Down's syndrome", Histopathology, vol. 13, pages 125-137 1988						
AP	SHOJI, Mikio et al. "Production of the Alzheimer Amyloid beta Protein by Normal Proteolytic Processing", Science, vol. 258, pages 126-129 1992						
AQ	MORI, Hiroshi et al. "Mass Spectrometry of Purified Amyloid beta Protein in Alzheimer's Disease", Journal of Biological Chemistry, vol. 267, no. 24, pages 17082-17086 1992						
Examiner				Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
		ATTY DOCKET NO. 270932US0PCT	
		SERIAL NO. 10/537246 New U.S. PCT Application Based on PCT/EP03/15033	
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT John Jairo LOPEZ AREIZA, et al.	
		FILING DATE Herewith	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	SOTO, Claudio. "Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches", J. Mol. Med., vol. 77, pages 412-418 1999		
AS	SERPELL, L.C. et al. "The molecular basis of amyloidosis", CMLS, vol. 53, pages 871-887 1997		
AT	SOTO, Claudio et al. "The alpha-Helical to beta-Strand Transition in the Amino-terminal Fragment of the Amyloid beta-Peptide Modulates Amyloid Formation", Journal of Biological Chemistry, vol. 270, no. 7, pages 3063-3067 1995		
AU	WISNIEWSKI, T. et al. "Therapeutics in Alzheimer's and Prion Diseases", Biochemical Society Transactions, vol. 30, part 4, pages 574-578 2002		
AV	YANKNER, Bruce A. "Mechanisms of Neuronal Degeneration in Alzheimer's Disease", Neuron, vol. 16, pages 921-932 1996		
AW	LEVINE, Harry III. "Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution", Protein Science, vol. 2, pages 404-410 1993		
AX	SOTO, Claudio et al. "Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy", Nature Medicine, vol. 4, no. 7, pages 822-826 1998		
AY	TRIGUERO, Domingo et al. "Capillary Depletion Method for Quantification of Blood-Brain Barrier Transport of Circulating Peptides and Plasma Proteins", Journal of Neurochemistry, vol. 54, pages 1882-1888 1990		
AZ			
AAA			
AAB			
AAC			
AAD			
AAE			
AAF			
AAG			
AAH			
Examiner		Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

101537246
JC17 Rec'd PCT/PTO 01 JUN 2005

New U.S. PCT Application Based on PCT/EP03/15033
Docket No.: 270932US0PCT

STATEMENT OF RELEVANCY

- 1) References AA, AB, AD-AF have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) References _____ have been cited in the corresponding _____ Search Report. A copy of these references is being submitted herewith.
- 3) References AC, AG-AY are discussed in the specification. A copy of these references is being submitted here with.
- 4) References _____ are additional prior art known to Applicant. A copy of these references is being submitted herewith.